On Monday, March 25, 2013, AstraZeneca UK Ltd. announced an agreement with Actavis Inc. and Egis Pharmaceuticals PLC, ending patent litigation over the “blockbuster cholesterol-reducing drug Crestor®.” In the deal, Actavis and Egis agreed not to launch a generic version of Crestor® until May 2016. Finnegan represented AstraZeneca in this matter.
Press Release
National Law Journal Names Finnegan D.C. IP Litigation Department of the Year
May 27, 2020
Media Mention
Revival of Aesthetic Functionality Doctrine Imperils Non-Traditional Marks, Panelists Say
March 13, 2012
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.